Clinical TrialJun 5, 2026, 06:07 AM
Immutep Presents Positive Interim Phase I Data for IMP761 at EULAR 2026
AI Summary
Immutep announced positive interim Phase I data for its lead autoimmune candidate, IMP761, at the EULAR 2026 Congress. The first-in-human study met its primary endpoint, demonstrating favorable safety and tolerability in healthy volunteers. IMP761 also showed statistically significant pharmacodynamic activity at 7 mg/kg, supporting further clinical investigation in autoimmune diseases. Additional trial updates are expected in H2 CY2026.
Key Highlights
- Phase I study for IMP761 met its primary endpoint, demonstrating favorable safety and tolerability.
- Statistically significant pharmacodynamic activity was observed at 7 mg/kg (p = 0.029).
- IMP761 was safe and very well tolerated across all tested dose levels (0.9 mg/kg to 7 mg/kg).
- Pharmacokinetics of single ascending doses support once per 4-week dosing.
- Additional trial updates for IMP761 are expected in H2 CY2026.
Price Impact
More from IMMP
More in Clinical Trial